… psoriasis vulgaris and generalized pustular psoriasis was first done by using intravenous
anti-CD4 monoclonal antibodies. … Two patients with severe, recalcitrant psoriasis vulgaris were …

… In this preliminary open trial, we report that one patient with generalized psoriatic erythroderma
and two patients with chronic extensive psoriasis resistant to other therapies responded …

… We treated 8 patients with severe to moderate psoriasis in an … the PASI as demonstrated in
our patients. This suggests that … of psoriatic skin lesions in our patients was due to infliximab. …

… There were 238 pregnancies reported in the Novartis global safety database in a cohort
of patients affected by psoriasis, psoriatic arthritis, and ankylosing spondylitis. It covers any …

… We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or
280 mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. At week 12, …

… a humanized monoclonal antibody directed against the CD11a subunit of LFA-1. This study
investigated whether treatment with anti-CD11a antibody provides clinical benefit to patients …

… A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New Eng J …
human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from …

… the use of monoclonal antibodies in the treatment of psoriasis. … -CD4 antibody has been
studied in the treatment of psoriasis. … in a patient with generalized pustular psoriasis 14 and in a …

… In this phase 3 trial, subcutaneous administration of the anti-interleukin-17A monoclonal
antibody secukinumab significantly improved the signs and symptoms of psoriatic arthritis …

… interleukin-17 with the humanized monoclonal antibody ixekizumab may be an effective
treatment for patients with chronic moderate-to-severe plaque psoriasis. At 12 weeks, significant …